Better Therapeutics At Your Doorstep, And Beyond
The Vaxess Microarray Patch (MAP) platform combines multiple breakthrough technologies that provide a better patient experience and improved access to transformative medicines.
Introducing the MAP Platform
The MAP platform is transforming medicinal delivery. The patch, resembling an adhesive bandage, is applied — painlessly — with a preloaded applicator and removed after a few minutes; no sharps bin required. Once applied, each patch delivers bioactive tips into the skin. These bioactive tips dissolve into the body after the patch is removed, rapidly releasing their payload of therapeutics.
Facilitating simple, pain-free, broadly distributed delivery of therapeutics
and biologics.
MAP in Action
Once placed on the skin, each MAP patch delivers a microarray of slow-release, bioactive tips into the skin. These bioactive tips gradually dissolve into the body after the patch is removed.
Easy and Accessible
The MAP platform is designed for efficient, remote delivery and simple, short wear time. At home, on the go, or into extreme environments - MAP can be self-applied and goes where traditional therapeutics can't. For patients, receiving a therapeutic like GLP-1 through MAP provides a better experience compared to injections while retaining the same efficacy.
Flexible and Consistent
The MAP platform’s biggest strengths and primary points of differentiation are consistency and flexibility. Vaxess’s in-house GMP manufacturing accommodates variable array sizes, enabling the platform to deliver a wide range of payloads and doses. Dissolving tips delivered with an applicator allow the MAP platform to deliver doses more consistently and effectively than competition.
Refrigeration-free
Vaxess’s MAP platform keeps therapeutics stable at room temperature, eliminating the burden and cost associated with cold chain. This makes it less expensive to ship and store therapeutics, and easier for people to deliver or transport therapeutics while on the go — increasing access and adherence.
Molecular Versatility
Vaxess has generated strong preclinical and clinical data, delivering a range of molecules with the MAP platform, demonstrating flexibility.
MAP can accommodate: therapeutic peptides and proteins, adjuvanted vaccines, live viruses and virus-like particles, inactivated viruses, and mRNA.
Scalable Manufacturing
Vaxess’ GMP facility was built to flexibly accommodate a range of molecules, large and small. The line was built to support rapid production of products into Phase I and Phase II clinical trials. Vaxess is actively automating and scaling it’s manufacturing capability to enable production of patches at 25M and 100M scale annually.